| Patent Number |
Title Of Patent |
Date Issued |
| 7608256 |
Methods to increase transgene expression from bacterial-based delivery systems by co-expressing |
October 27, 2009 |
| Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon resp |
| 7235234 |
Bacterial delivery system |
June 26, 2007 |
| We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA and antigens into the cell cytoplasm. This Shigella vector was designed to |
| 7045336 |
Bacterial delivery system |
May 16, 2006 |
| We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA and antigens into the cell cytoplasm. This Shigella vector was designed to |
| 6872398 |
Conjugate vaccine against gram-negative bacterial infections |
March 29, 2005 |
| The present invention relates to a broadly reactive vaccine against Gram-negative bacteria which is composed of a biological glycan-pilus conjugate. The conjugate core is a common pilus type to which is attached the glycan of choice in vivo. Pooling of these bioconjugates produces a |
| 6410012 |
Antimicrobial mediated bacterial DNA delivery |
June 25, 2002 |
| This invention pertains in part to a method for delivering functional DNA or antigens. The desired DNA is introduced into attenuated bacteria able to enter cells. Once the bacteria is in the cell, antimicrobial agents are introduced such that they enter the mammalian cell and lyse the ba |
| 6315999 |
Pharmaceutical product for the treatment of sepsis |
November 13, 2001 |
| An antibody to tumor necrosis factor-.alpha. (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each o |
| 6224880 |
Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal pol |
May 1, 2001 |
| A method of immunizing against disease caused by Streptococcus pneumoniae is provided in which children are immunized at age 2 and again at age 4 months with a conjugated pneumococcal polysaccharide vaccine. These immunizations are followed by an immunization at 6 months with an unco |
| 5824538 |
Shigella vector for delivering DNA to a mammalian cell |
October 20, 1998 |
| We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA, such as a mammalian expression plasmid, and antigens into the cell cytop |
| 4285936 |
Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa |
August 25, 1981 |
| A method for isolating a non toxic, high molecular weight polysaccharide igen from the crude slime of a Pseudomonas aeruginosa culture, and a method for inducing immunity in a host to said live organisms is described. The slime is initially prepared for the isolation procedure by se |
